Tectonic Therapeutic, Inc.

Equities

AVRO

US8789721086

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 29/06/2024 am IST			5-day change	1st Jan Change
16.47 ^USD	-0.12%		-3.17%	+0.92%

20/06	Avrobio Closes Merger With Tectonic Therapeutic	MT
20/06	Tectonic Therapeutic, Inc. announced that it has received $96.599856 million in funding from Tas Partners, LLC	CI

Avrobio, Inc. Announces Appointment of Katina Dorton as Chief Financial Officer

September 26, 2017 at 05:35 pm IST

AVROBIO Inc. announced the appointment of Katina Dorton as Chief Financial Officer. Ms. Dorton has served as a senior strategic and financing advisor to numerous companies in the life sciences and biotechnology sectors. Prior to joining AVROBIO, Ms. Dorton served as Chief Financial Officer of Immatics GmbH.

Latest news about Tectonic Therapeutic, Inc.

Avrobio Closes Merger With Tectonic Therapeutic	21/06	MT
Tectonic Therapeutic, Inc. announced that it has received $96.599856 million in funding from Tas Partners, LLC	20/06	CI
AVROBIO, Inc.(NasdaqGS:AVRO) dropped from NASDAQ Composite Index	20/06	CI
Tectonic Therapeutic, Inc. completed the acquisition of AVROBIO, Inc. from a group of shareholders in a reverse merger transaction.	20/06	CI
Avrobio Insider Bought Shares Worth $971,493, According to a Recent SEC Filing	15/05	MT
AVROBIO, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05	CI
North American Morning Briefing : Investors -2-	21/03	DJ
AVROBIO, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	15/03	CI
Transcript : AVROBIO, Inc., Tectonic Therapeutic, Inc. - M&A Call	30/01
Tectonic Therapeutic, Inc. announced that it expects to receive $96.599856 million in funding from Tas Partners, LLC	30/01	CI
AVROBIO, Inc. entered into an agreement to acquire Tectonic Therapeutic, Inc.	30/01	CI
North American Morning Briefing : S&P 500 Eyes -2-	19/12	DJ
Mizuho Securities Cuts Avrobio Price Target to $2 From $5, Buy Rating Kept	18/12	MT
North American Morning Briefing : Caution Dominates Ahead of CPI Print	14/11	DJ
AVROBIO, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
North American Morning Briefing : China Angst -2-	15/23/15	DJ
AVROBIO, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11	CI
Wells Fargo Adjusts Price Target on AVROBIO to $2 From $2.50, Maintains Overweight Rating	13/23/13	MT
North American Morning Briefing : Optimism Set to -2-	13/23/13	DJ
Sector Update: Health Care Stocks Slipping Late Wednesday	13/23/13	MT
Sector Update: Health Care Stocks Softer in Afternoon Trading	12/23/12	MT
Wedbush Downgrades AVROBIO to Neutral From Outperform on Halted Development of Gene Therapy Programs, Exploring Alternatives; PT is $2	12/23/12	MT
AVROBIO Says Exploring Strategic Alternatives to Boost Shareholder Value; Shares Jump	12/23/12	MT
Avrobio to Conduct Exploration of Strategic Alternatives	12/23/12	CI
AVROBIO, Inc.(NasdaqGS:AVRO) dropped from Russell Microcap Index	23/23/23	CI

Chart Tectonic Therapeutic, Inc.

Duration

Period

More charts

Company Profile

Tectonic Therapeutic, Inc. is a biotechnology company. The Company is focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs). Leveraging its technology platform called GEODe (GPCRs Engineered for Optimal Discovery), the Company is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. The Companyâs lead program, TX000045 (TX45), is an Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone relaxin. TX45 is being evaluated in Phase Ia/Ib clinical trials as a potential treatment for Group 2 Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (HFpEF). Its second program addresses Hereditary Hemorrhagic Telangiectasia (HHT).

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

16.47 USD

Average target price

76 USD

Spread / Average Target

+361.45%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
TECTONIC THERAPEUTIC, INC.	+0.92%	24Cr
VERTEX PHARMACEUTICALS INCORPORATED	+15.20%	12TCr
REGENERON PHARMACEUTICALS, INC.	+19.67%	11TCr
ARGENX SE	+18.95%	2.6TCr
BIONTECH SE	-23.86%	1.94TCr
GENMAB A/S	-19.03%	1.59TCr
BEIGENE, LTD.	-20.90%	1.51TCr
WUXI APPTEC CO., LTD.	-46.14%	1.51TCr
SAREPTA THERAPEUTICS, INC.	+63.85%	1.49TCr
NEUROCRINE BIOSCIENCES, INC.	+4.49%	1.39TCr

Bio Therapeutic Drugs